# Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

> **NCT03366103** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Malignant Solid Neoplasm
- Recurrent Lung Small Cell Carcinoma
- Recurrent Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7
- Stage IIIA Lung Small Cell Carcinoma AJCC v7
- Stage IIIB Lung Small Cell Carcinoma AJCC v7
- Stage IV Lung Small Cell Carcinoma AJCC v7
- Unresectable Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Navitoclax
- **DRUG:** Vistusertib

## Key facts

- **NCT ID:** NCT03366103
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-20
- **Primary completion:** 2021-07-28
- **Final completion:** 2022-09-21
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Drug supply issues
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366103, "Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03366103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*